Amgen, headquartered in Thousand Oaks, California, is a biotechnology company employing 26,700 staff, focusing on developing human therapeutics for high unmet medical needs. Its product portfolio includes Aranesp, ENBREL, and Prolia, among others.
Matthew C Busch sold 1,000 shares of AMGN on 2 May at $279.69 per share, worth a total of $280K. They now own 4,034 AMGN shares, or a 20% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
